HC Wainwright Cuts Earnings Estimates for Alpha Tau Medical

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Stock analysts at HC Wainwright decreased their FY2025 EPS estimates for shares of Alpha Tau Medical in a research report issued to clients and investors on Monday, March 17th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.53) for the year, down from their previous forecast of ($0.50). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.45) per share.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13).

Alpha Tau Medical Price Performance

Shares of NASDAQ:DRTS opened at $2.60 on Wednesday. The firm has a fifty day moving average price of $3.21 and a two-hundred day moving average price of $2.79. Alpha Tau Medical has a one year low of $1.75 and a one year high of $4.39. The company has a market cap of $181.80 million, a price-to-earnings ratio of -6.05 and a beta of 0.87.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DRTS. Renaissance Technologies LLC boosted its holdings in Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after purchasing an additional 26,800 shares during the period. Northern Trust Corp lifted its holdings in shares of Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock worth $151,000 after acquiring an additional 25,770 shares during the last quarter. Finally, Levin Capital Strategies L.P. lifted its holdings in shares of Alpha Tau Medical by 2.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock worth $975,000 after acquiring an additional 7,189 shares during the last quarter. 2.65% of the stock is owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.